PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

23 أبريل 2025 10:16:57 بحسب Nasdaq GlobeNewswire

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

16 أبريل 2025 08:00:00 بحسب Nasdaq GlobeNewswire

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

08 أبريل 2025 08:00:15 بحسب Nasdaq GlobeNewswire

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

27 مارس 2025 07:30:00 بحسب Nasdaq GlobeNewswire

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

25 مارس 2025 08:00:32 بحسب Nasdaq GlobeNewswire

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

18 مارس 2025 08:00:01 بحسب Nasdaq GlobeNewswire

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

13 مارس 2025 08:00:00 بحسب Nasdaq GlobeNewswire

PDS Biotech Leadership to Participate in March Conferences

11 مارس 2025 08:00:00 بحسب Nasdaq GlobeNewswire

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

07 مارس 2025 08:45:00 بحسب Nasdaq GlobeNewswire

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

27 فبراير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

26 فبراير 2025 08:00:01 بحسب Nasdaq GlobeNewswire

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

24 فبراير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

20 فبراير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

05 فبراير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06 ديسمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

03 ديسمبر 2024 08:00:33 بحسب Nasdaq GlobeNewswire

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

14 نوفمبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

06 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

22 أكتوبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

02 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire